65,437 trials
Chronic Hepatitis C Virus (HCV) Infection Genotype 1
Primary: All-Cause Death: Time to Event — 8.3; 0.1; 8.3; 0.7 percentage of participants — p=<0.001
Malignant PEComa
Primary: Objective Overall Response Rate (ORR) — 2; 10; 16; 3 Participants
Osteoporosis · Osteoporosis, Age-Related · Osteoporosis Localized to Spine
Primary: Percent Change From Baseline in Lumbar Spine BMD at Month 12 — 8.4820; 1.1654 percent change — p=<0.0001
Excessive Bleeding During Surgery
Primary: Percentage of Participants Achieving Hemostasis Within 4 Minutes After Treatment Start (T4) — 100.0; 100.0; 93.3; 90.9 percentage of participants — p=< 0.001
Disruptive Behavior
Primary: CFI Clinician Questionnaire — 4.2; 4.1; 3.8; 3.6 units on a scale
Stage IV Non-Small Cell Lung Cancer
Primary: Progression Free Survival — 3.5; 9.7 months — p=.01
Obstructive Sleep Apnea
Primary: Apnea-Hypopnea Index (AHI)4% Events Per Hour — 28.6; 26.6 events/hour
Asthma
Primary: Proportion of Days Covered (PDC) — 0.39; 0.33 proportion of days
Chronic Pain
Primary: Daily Opioid Morphine Milligram Equivalents (MME) — 65.17; 67.51 MME/day — p=0.58
Kidney Calculi · Urologic Diseases · Benign Prostatic Hypertrophy
Primary: Same-day Discharge Rate — 50; 49 Participants
Psychotic Disorders · Psychosis · Psychotic Episode
Primary: Change in the Number of Mental Health Related Appointments Attended by the Individual With Psychosis (IP) in the Past 30 Days — 0.29; -1.06 number of appointments
Respiratory Syncytial Virus Infections
Primary: Number of Participants Reporting Any Serious Adverse Events (SAEs) — 0; 0; 0 Participants
Myelokathexis · Infections · Neutropenia
Primary: Severity of Infection — 12.5; 9 score on a scale (with no maximum)
Cigarette Smoking-Related Carcinoma
Primary: Satisfaction With Assigned Treatment — 0; 1; 17; 18 Participants — p=.999
COVID-19
Primary: Number of New COVID-19 Detected Infections Among Residents — 0; 0 Infections